GlaxoSmithKline plc and Innoviva, Inc announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg).

At the signing ceremony of the new research collaboration: Back row from left: Dr. Simone Gatzke, Forschungszentrum Juelich, Raphael Dumain, Dr. Isolde Häuser-Hahn and Dr. habil Guenter Welz from Bayer, Prof. Ulrich Schurr, Juelich, Dr. Samir Bennabi, Bayer.

Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, announced that they have entered into a research collaborationwith the objective to discover and develop novel compounds for the treatment of schizophrenia.

Advaxis, Inc a clinical stage biotechnology company developing cancer immunotherapies, will unveil its new state-of-the-art manufacturing facility in Princeton, N.J., with remarks from Governor Chris Christie, BioNJ President and CEO Debbie Hart and Advaxis CEO Daniel O’Connor.

Results from pivotal Phase III trials presented at the ERS International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.

CiToxLAB, a leading CRO in the field of non-clinical research, announces that Alan Bartlett has joined the company as Senior Director, Global Laboratory Operations, bringing with him 30 years’ experience in the development and implementation of laboratory support in preclinical and clinical research.

Dr. Reddy’s Laboratories Ltd announced that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin® SR (bupropion HCl) Sustained-Release Tablets in the United States market approved by the U.S. FDA.

Preliminary data from the world’s first national meningitis B immunisation programme with Bexsero1, launched one year ago in the UK, shows the estimated effectiveness of the vaccine at 83 percent against any meningitis B strain and 94 percent.

AstraZeneca announced that it has completed the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US.

Bizerba’s solution portfolio now includes filling systems as well. Following the merger with Busch, a Swiss company, the weighing specialist now integrates competencies in filling technology into the companies’ joint portfolio. Bizerba’s fully and semi-automatic filling solutions target the chemical, food, building material, paint and lacquer and pharmaceutical industries.

Wipak Distinctly Different Sustainable Laminate Solutions, including new and innovative applications of paper and plastic laminates for cheese, sausages and more.

Perigord, innovators in Life Science Artwork Management Services and Solutions, and GlobalVision, leaders in the design and delivery of Innovative Proofreading Technologies announced their alliance for the integration of their artwork management systems in order to better service the Life Science Industries.